Resistensi Treponema pallidum terhadap Makrolida Sebagai Pengobatan Alternatif Sifilis
Keywords:
Syphilis, Treponema pallidum, resistance, macrolideAbstract
Treponema pallidum (T. pallidum) is a pathogen that causes syphilis, which is transmitted through contact with active lesions of a sex partner or an infected pregnant woman to her fetus. Despite various aggressive efforts and pharmacological treatments, syphilis has persisted and continues to be a health problem, even experiencing an increase in the prevalence of the disease in recent years. This article is based on literature studies on various research published online, especially on Google Scholar, ScienceDirect, Scopus, Pubmed, and other scientific journals. The studies were then synthesized into comprehensive information regarding specific resistance mechanisms of T. pallidum bacteria to several antibiotics. Macrolide, especially azithromycin, is an alternative treatment that is most often used in the treatment of syphilis in addition to first-line antibiotics, benzathine penicillin G injection. The use of its single oral dose, its effectiveness equivalent to penicillin, cost-effectiveness, and rare side-effect profile made azithromycin widely used in the treatment of syphilis in various regions throughout the world until treatment failures were reported. The mechanism of resistance to macrolides occurs due to modification of the antibiotic target site (binding site) caused by mutations in the 23S rRNA gene. The increase in cases and the emergence of clinically significant resistance to alternative antibiotics in some countries emphasize the urgent need for vigilance. Knowledge and understanding of the resistance mechanism of Treponema pallidum to antibiotics, especially the macrolides group, is essential in line with the increasing resistance of Treponema pallidum to antibiotics globally.
References
Blair JMA, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJV. (2015). Molecular mechanisms of antibiotic resistance. Nat Rev Microbiol. 13(1):42-51.
Cameron CE. (2018). Syphilis vaccine development: requirements, challenges and opportunities. Sex Transm Dis. 45(9): S17–S19.
Chen XS, Yin YP, Wei WH, Wang HC, Peng RR, Zheng JP, Zhu BY, Liu QZ, et al. (2013). High prevalence of azithromycin resistance to Treponema pallidum in geographically different areas in China. Clin Microbiol Infect. 19(10): 975-9.
Corona F, Martinez JL. (2013). Phenotypic resistance to antibiotics. Antibiotics (Basel). 2(2): 237-255.
Deck DH, Winston LG. (2012). Antimycobacterial drugs. In: Katzung BG, Masters SB, Trevor AJ, Basic and clinical pharmacology, 12th ed., McGraw-Hill, New York.
Gaynor M, Mankin AS. (2003). Macrolide antibiotics: binding site, mechanism of action, resistance. Curr Top Med Chem. 3(9): 949-961.
Giedraitienė A, Vitkauskienė A, Naginienė R, Pavilonis A. (2011). Antibiotic resistance mechanisms of clinically important bacteria. Medicina (Kaunas). 47(3):137-46.
Ho EL, Lukehart SA. (2011). Syphilis: using modern approaches to understand an old disease. J Clin Invest.121(12):4584-4592.
Kent ME, Romanelli F. (2008). Reexamining syphilis: an update on epidemiology, clinical manifestations, and management. The Annals of Pharmacotheraphy. 42(2):226-236.
Kenyon C. (2019). Prevalence of macrolide resistance in Treponema pallidum is associated with macrolide consumption. J Med Microbiol. 68(2):119–123.
LaFond RE, Lukehart SA. (2006). Biological basis for syphilis. Clin Microbiol Rev. 19(1): 29–49.
Marra CM, Sahi SK, Tantalo LC, Godornes C, Reid T, et al. (2010). Enhanced molecular typing of Treponema pallidum: geographical distribution of strain types and association with neurosyphilis. J Infect Dis. 202(9):1380–1388.
Matějková P, Flasarová M, Zákoucká H, Bořek M, et al. (2009). Macrolide treatment failure in a case of secondary syphilis: a novel A2059G mutation in the 23S rRNA gene of Treponema pallidum subsp. Pallidum. J Med Microbiol. 58(Pt 6):832–836.
Radolf JD, Deka RK, Anand A, Šmajs D, Norgard MV, Yang XF. (2016). Treponema pallidum, the syphilis spirochete: making a living as a stealth pathogen. Nat Rev Microbiol.14(12):744-759.
Stamm LV. (2010). Minireview global challenge of antibiotic-resistant Treponema pallidum. Antimicrob Agents Chemother. 54 (2): 583–589.
Stamm LV. (2014). Syphilis: antibiotic treatment and resistance. Epidemiol. Infect. 143(8):1-8.
Tenover, FC. (2006). Mechanisms of antimicrobial resistance in bacteria. Am J Med. 119 (6A): S3–S10.
Tipple C. (2013). Thesis submitted in fulfillment of the requirements for the degree of Doctor of Philosophy of Imperial College London.
Tipple C, McClure MO, Taylor GP. (2011). High prevalence of macrolide resistant Treponema pallidum strains in a London centre. Sex Transm Infect. 87(6): 486 - 488.
Tipple C, Taylor GP. 2015. Syphilis testing, typing, and treatment follow-up: a new era for an old disease. Curr Opin Infect Dis. 28(1):53–60.
Vester B, Douthwaite S. (2001). Macrolide resistance conferred by base substitutions in 23s rRNA. Antimicrob Agents Chemother. 45(1): 1–12.
Walsh C. (2000). Molecular mechanisms that confer antibacterial drug resistance. Nature. 406(6797): 775-781.
WHO. (2005). Prevalence and Incidence of selected sexually transmitted infections Chlamydia trachomatis, Neisseria gonorrhoeae, syphilis and Trichomonas vaginalis: methods and result used by WHO to generate 2005 estimates.
World Health Organization. (2016). WHO guidelines for the treatment of Treponema pallidum (syphilis). WHO Press, Geneva, Switzerland.
Wu H, Chang SY, Lee NY, Huang WH, et al. (2012). Evaluation of macrolide resistance and enhanced molecular typing of Treponema pallidum in patients with syphilis in Taiwan: a prospective multicenter study. Journal of Clinical Microbiology. 50(7): 2299–2304.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Desy Ariani Gultom
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
.svg_.png){kind=logo}
